...
首页> 外文期刊>Magnetic resonance imaging: An International journal of basic research and clinical applications >Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling
【24h】

Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling

机译:使用MR光谱,灌注MR成像或体积进展模型对分级放射治疗或立体定向放射外科手术后的轴向内转移性肿瘤进展与放射损伤的区别

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To determine the accuracy of magnetic resonance spectroscopy (MRS), perfusion MR imaging (MRP), or volume modeling in distinguishing tumor progression from radiation injury following radiotherapy for brain metastasis. Methods: Twenty-six patients with 33 intra-axial metastatic lesions who underwent MRS (n=41) with or without MRP (n=32) after cranial irradiation were retrospectively studied. The final diagnosis was based on histopathology (n=4) or magnetic resonance imaging (MRI) follow-up with clinical correlation (n=29). Cho/Cr (choline/creatinine), Cho/NAA (choline/. N-acetylaspartate), ChoCho (choline/contralateral normal brain choline) ratios were retrospectively calculated for the multi-voxel MRS. Relative cerebral blood volume (rCBV), relative peak height (rPH) and percentage of signal-intensity recovery (PSR) were also retrospectively derived for the MRPs. Tumor volumes were determined using manual segmentation method and analyzed using different volume progression modeling. Different ratios or models were tested and plotted on the receiver operating characteristic curve (ROC), with their performances quantified as area under the ROC curve (AUC). MRI follow-up time was calculated from the date of initial radiotherapy until the last MRI or the last MRI before surgical diagnosis. Results: Median MRI follow-up was 16 months (range: 2-33). Thirty percent of lesions (n=10) were determined to be radiation injury; 70% (n=23) were determined to be tumor progression. For the MRS, ChoCho had the best performance (AUC of 0.612), and ChoCho >1.2 had 33% sensitivity and 100% specificity in predicting tumor progression. For the MRP, rCBV had the best performance (AUC of 0.802), and rCBV >2 had 56% sensitivity and 100% specificity. The best volume model was percent increase (AUC of 0.891); 65% tumor volume increase had 100% sensitivity and 80% specificity. Conclusion: ChoCho of MRS, rCBV of MRP, and percent increase of MRI volume modeling provide the best discrimination of intra-axial metastatic tumor progression from radiation injury for their respective modalities. ChoCho and rCBV appear to have high specificities but low sensitivities. In contrast, percent volume increase of 65% can be a highly sensitive and moderately specific predictor for tumor progression after radiotherapy. Future incorporation of 65% volume increase as a pretest selection criterion may compensate for the low sensitivities of MRS and MRP.
机译:为了确定磁共振波谱(MRS),灌注MR成像(MRP)或体积模型在区分肿瘤进展与放射治疗后脑转移的放射损伤方面的准确性。方法:回顾性分析了26例33例轴向内转移性病变患者的颅骨放疗后行MRS(n = 41)或不行MRP(n = 32)的情况。最终诊断基于组织病理学(n = 4)或磁共振成像(MRI)随访,并具有临床相关性(n = 29)。回顾性地计算了多体素MRS的Cho / Cr(胆碱/肌酐),Cho / NAA(胆碱/ N-乙酰天门冬氨酸),Cho / nCho(胆碱/对侧正常脑胆碱)比率。还回顾性地得出了MRP的相对脑血容量(rCBV),相对峰高(rPH)和信号强度恢复百分比(PSR)。使用手动分割方法确定肿瘤体积,并使用不同的体积进展模型进行分析。测试了不同的比率或模型,并绘制在接收器工作特性曲线(ROC)上,其性能量化为ROC曲线(AUC)下的面积。从首次放疗之日至最后一次MRI或手术诊断前的最后MRI,计算MRI的随访时间。结果:MRI中位随访时间为16个月(范围:2-33)。百分之三十的病变(n = 10)被确定为辐射损伤; 70%(n = 23)被确定为肿瘤进展。对于MRS,Cho / nCho的性能最佳(AUC为0.612),而Cho / nCho> 1.2的33%敏感性和100%特异性可预测肿瘤进展。对于MRP,rCBV具有最佳性能(AUC为0.802),rCBV> 2具有56%的敏感性和100%的特异性。最佳的体积模型是百分比增长(AUC为0.891);肿瘤体积增加65%具有100%的敏感性和80%的特异性。结论:MRS的Cho / nCho,MRP的rCBV以及MRI体积建模的百分比可根据其各自的方式对放射损伤引起的轴内转移性肿瘤进展进行最佳区分。 Cho / nCho和rCBV似乎具有高特异性,但敏感性低。相反,体积增加百分比为65%可能是放疗后肿瘤进展的高度敏感和中等特异性的预测指标。未来将增加65%的体积作为预先测试的选择标准可能会弥补MRS和MRP的低敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号